BCLC分期C期肝细胞癌不同治疗方案的效果及预后影响因素分析

陆冬玲; 朱玉平; 欧杰; 毛素菲; 邬国斌; 何剑波; 黄山; 陈闯

doi:10.3969/j.issn.1001-5256.2018.09.016

BCLC分期C期肝细胞癌不同治疗方案的效果及预后影响因素分析

DOI: 10.3969/j.issn.1001-5256.2018.09.016

1. 贵州省骨科医院内科
2. 广西医科大学附属肿瘤医院中医科

基金项目:

广西科学研究与技术开发计划项目(桂攻科1598012-54)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 3007
- HTML全文浏览量: 42
- PDF下载量: 334
- 被引次数: 0
出版历程
- 收稿日期: 2018-02-26
- 出版日期: 2018-09-20

Clinical effects of different treatment regimens for Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma and influencing factors for prognosis

Department of Internal Medicine, Guizhou Orthopedics Hospital

Research funding:

摘要

摘要: 目的分析巴塞罗那肝癌临床分期（BCLC）C期肝细胞癌（HCC）的不同治疗方案及预后影响因素。方法回顾性分析2005年1月-2012年12月在广西医科大学附属肿瘤医院首次诊断并治疗的BCLC C期HCC患者的临床资料。按照治疗方案分为:单纯经肝动脉化疗栓塞术（TACE）组（n=20）、TACE+索拉非尼组（n=18）、TACE+消融组（n=17）、手术+TACE组（n=20）、手术+TACE+消融组（n=16）。随访并记录患者生存状况及具体死亡时间,比较各组生存期。计数资料组间比较采用χ2检验,计量资料组间比较采用方差分析;采用Kaplan-Meier绘制总生存率曲线,采用log-rank比较累积生存率,采用Cox回归模型行单因素、多因素分析。结果共纳入HCC患者91例,随访终止日期为2016年11月1日,随访率为100%。单因素分析结果显示,年龄、肝外转移、肿块类型、肿瘤最大直径、治疗方案等是BCLC C期HCC预后的影响因素（P值均<0.05）。多因素结果显示,年龄（P=0.019）、肿瘤最大直径（P=0.018）、肝外转移（P=0.026）、治疗方案（P=0.006）是HCC...
- 癌,肝细胞 /
- 化学栓塞,治疗性 /
- 导管消融术 /
- 索拉非尼 /
- 预后 /
- 危险因素
Abstract: Objective To investigate the clinical effects of different treatment regimens for Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) and influencing factors for prognosis. Methods A retrospective analysis was performed for the clinical data of 91 patients with BCLC stage C HCC who were diagnosed and treated in The Affiliated Tumor Hospital of Guangxi Medical University from January 2005 to December 2012. According to the treatment regimen, these patients were divided into transarterial chemoembolization (TACE) group with 20 patients, TACE + sorafenib group with 18 patients, TACE + ablation group with 17 patients, surgery + TACE group with 20 patients, and surgery + TACE + ablation group with 16 patients. The patients were followed up to record survival and death time, and survival time was compared between groups. The chi-square test was used for comparison of categorical data between groups, and an analysis of variance was used for comparison of continuous data between groups. The Kaplan-Meier method was used to plot overall survival curves, and the log-rank test was used for comparison of cumulative survival rates. The Cox regression model was used for univariate and multivariate analyses. Results A total of 91 HCC patients were enrolled, and follow-up ended on November 1, 2016, with a follow-up rate of 100%. The univariate analysis showed that age, extrahepatic metastasis, tumor type, maximum tumor diameter, and treatment regimen were influencing factors for the prognosis of BCLC stage C HCC (all P < 0. 05) , and the multivariate analysis showed that age (P =0. 019) , maximum tumor diameter (P = 0. 018) , extrahepatic metastasis (P = 0. 026) , and treatment regimen (P = 0. 006) were independent influencing factors for the prognosis of HCC. There was a significant difference in overall survival between groups (χ2= 22. 841, P < 0. 001) . The surgery + TACE + ablation group had a significantly longer overall survival time than the other four groups (all P < 0. 05) ;the TACE + ablation group had a significantly longer overall survival time than the TACE group and the TACE + sorafenib group (P < 0. 05) ;the surgery + TACE group had a significantly longer overall survival time than the TACE group and the TACE + sorafenib group (P < 0. 05) .Conclusion Age, maximum tumor diameter, extrahepatic metastasis, and treatment regimen are independent influencing factors for the prognosis of BCLC stage C HCC. Surgical treatment should be selected for resectable stage C HCC, and TACE should be performed after surgery to prevent recurrence. TACE or ablation should be performed after recurrence, and surgical resection can be performed again when possible. TACE combined with ablation should be performed for unresectable stage C HCC, and the advantages of these two treatment methods can improve overall survival time.
- carcinoma, hepatocellular /
- chemoembolization, therapeutic /
- catheter ablation /
- sorafenib /
- prognosis /
- risk factors

HTML全文

参考文献(19)

[1]TORRE LA, BRAY F, SIEGEL RL, et al.Global cancer statistics, 2012[J].CA Cancer J Clin, 2015, 65 (2) :87-108.

[2]The Minister of Health of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V2011) [J].JClin Hepatol, 2011, 27 (11) :1141-1159. (in Chinese) 中华人民共和国卫生部.原发性肝癌诊疗规范 (2011年版) [J].临床肝胆病杂志, 2011, 27 (11) :1141-1159.

[3]LLOVET JM, BRU'C, BRUIX J.Bruix prognosis of hepatocellular carcinoma:The BCLC staging classification[J].Semin Liver Dis, 1999, 19 (3) :329-338.

[4]LIANG HY, LU ZM.Current status and confusion in comprehensive interventional therapy for hepatocellular carcinoma[J].J Clin Hepatol, 2016, 32 (1) :44-48. (in Chinese) 梁宏元, 卢再鸣.原发性肝癌综合介入治疗现状与困惑[J].临床肝胆病杂志, 2016, 32 (1) :44-48.

[5]YANG T, LI C, ZHAI J, et al.Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging[J].J Cancer Res Clin Oncol, 2012, 138 (7) :1121-1129.

[6]PESI B, FERRERO A, GRAZI GL, et al.Liver resection with thrombectomy as a treatment of hepatocellular carcinoma with major vascular invasion:Results from a retrospective multicentric study[J].Am J Surg, 2015, 210 (1) :35-44.

[7]LI L, TIAN J, LIU P, et al.Transarterial chemoembolization combination therapy vs monotherapy in unresectable hepatocellular carcinoma:A meta-analysis[J].Tumori, 2016, 2016 (3) :301-310.

[8]XU C, LV PH, HUANG XE, et al.Efficacy of transarterial chemoembolization combined with radiofrequency ablation in treatment of hepatocellular carcinoma[J].Asian Pac J Cancer Prev, 2015, 16 (14) :6159-6162.

[9]WANG DY, LIU L, QI XS, et al.Hepatic re-resection versus transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma after initial resection:A systematic review and meta-analysis[J].Asian Pac J Cancer Prev, 2015, 16 (13) :5573-5578.

[10]XING ZX, SHEN SQ, QIN F, et al.Effect of postoperative adjuvant transarterial chemoembolization on postoperative survival of patients with liver cancer and related influencing factors for prognosis[J].JClin Hepatol, 2017, 33 (12) :2331-2336. (in Chinese) 邢志祥, 沈世强, 秦峰, 等.肝癌切除术后辅助性经肝动脉化疗栓塞术对息者生存的影响及预后相关因素分析[J].临床肝胆病杂志, 2017, 33 (12) :2331-2336.

[11]YE JZ, ZHANG YQ, YE HH, et al.Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus[J].World J Gastroenterol, 2014, 20 (45) :17141-17147.

[12]PENG ZW, ZHANG YJ, CHEN MS, et al.Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma:A prospective randomized trial[J].J Clin Oncol, 2013, 31 (4) :426-432.

[13]SHIM JH, PARK JW, KIM JH, et al.Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients[J].Cancer Sci, 2008, 99 (10) :2037-2044.

[14]ZHANG X, WANG K, WANG M, et al.Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus:A systematic review and meta-analysis[J].Oncotarget, 2017, 8 (17) :29416-29427.

[15]KUDO M, IMANAKA K, CHIDA N, et al.Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma[J].Eur J Cancer, 2011, 47 (14) :2117-2127.

[16]KOW AW, KWON CH, SONG S, et al.Risk factors of peritoneal recurrence and outcome of resected peritoneal recurrence after liver resection in hepatocellular carcinoma:Review of 1222 cases of hepatectomy in a tertiary institution[J].Ann Surg Oncol, 2012, 19 (7) :2246-2255.

[17]CHEN YB, ZHANG JJ, MENG XK.Research progress on the prognostic factors of primary liver cancer[J].J Hepatopancreatobiliary Surg, 2015, 27 (2) :164-166. (in Chinese) 陈一博, 张俊晶, 孟兴凯.原发性肝癌预后影响因素的研究进展[J].肝胆胰外科杂志, 2015, 27 (2) :164-166.

[18]CAO GL, CAI Q, LI YA, et al.Risk factors analysis and prognosis of the microvascular invasion of hepatocellular carcinoma[J].Chin JDig Surg, 2017, 16 (10) :1048-1052. (in Chinese) 曹国良, 蔡庆, 李幼安, 等.肝细胞癌微血管侵犯的危险因素分析及预后[J].中华消化外科杂志, 2017, 16 (10) :1048-1052.

[19]WAKAYAMA K, KAMIYAMA T, YOKOO H, et al.Huge hepatocellular carcinoma greater than 10 cm in diameter worsens prognosis by causing distant recurrence after curative resection[J].J Surg Oncol, 2017, 115 (3) :324-329.

施引文献

资源附件(0)

访问统计